METABOLIC & BARIATRIC SCIENCES

Vol. 2, Issue 15   |   October 20, 2026

Cancer and survival outcomes extend the view beyond postoperative weight loss, while late thrombosis and nutritional findings complicate the benefit-risk picture. This issue also examines digital tirzepatide care, Revita maintenance data and oral-drug development.

A — Metabolic Surgery Research

Cecilia Radkiewicz, Giola Santoni, Joonas H. Kauppila et al. | JAMA Surgery, Oct. 14, 2026 | 10.1001/jamasurg.2026.4798
Suggested by Phil Schauer

Among 784,105 Nordic adults aged 18–59 with obesity, 99,614 underwent surgery. Surgery was associated with lower obesity-related cancer incidence (adjusted incidence rate ratio [aIRR], 0.81; 95% CI, 0.77–0.85). Age-at-entry estimates were similar: 0.80 for 18–39 and 0.81 for 40–59 (interaction P=.88). No age interaction was detected; the benefit is not equal across age groups.

Pancreatic cancer showed the opposite association: aIRR 1.19 (95% CI, 1.002–1.41) overall and 2.21 (1.44–3.39) at ages 18–39. The age interaction (P=.01) warrants replication, not a causal harm claim. The models adjusted for demographics and comorbidities but lacked BMI and direct lifestyle measures. Residual confounding and surveillance bias limit causal interpretation.

KEY FINDING

For non–sex-specific cancers, estimates were 0.94 in men and 0.98 in women; both confidence intervals included 1. No sex interaction was detected (P=.50), so we cannot conclude a protective effect in either sex.

Hector J. Garcia Navas, Shubham Bhatia, Nicholas Dahlgren et al. | Surgery for Obesity and Related Diseases, October 2026 | 10.1016/j.soard.2026.10.010
Suggested by John D. Scott, MD

Disclosure: Editorial Board member Philip R. Schauer is a coauthor.

A TriNetX analysis followed 88,689 sleeve and Roux-en-Y gastric bypass cases for 12 months and identified 184 portomesenteric thromboses. Sleeve accounted for 64% of operations, compared with 36% for bypass. The adjusted hazard ratio for sleeve versus bypass was 3.30 (95% CI, 2.12–5.13); among sleeve-associated events, 29% were diagnosed beyond the fourth postoperative week.

By week 8, researchers diagnosed 82% of sleeve-associated thromboses, compared with 56% after bypass. The timing matters because a 30-day complication window misses part of the postoperative burden, particularly after sleeve. Anticoagulant dose, duration and adherence were unavailable, so the study cannot establish whether longer chemoprophylaxis would prevent these later events.

KEY FINDING

29% of sleeve-associated thromboses were diagnosed after week 4. The event distribution extends beyond the usual 30-day reporting window.

Kai He, Marcus H. Cunningham, Iwanger-I-Ter T. Jia et al. | Surgery for Obesity and Related Diseases, October 2026 | 10.1016/j.soard.2026.10.009
Suggested by John D. Scott, MD

A meta-analysis of 34 studies with 449,957 patients compared mortality after bariatric surgery with nonsurgical care. At 7 years, pooled mortality was 1.64% after RYGB, 0.76% after sleeve, and 2.64% in controls. At 12 years, RYGB mortality was 4.34% versus 7.11% in controls, extending the survival association beyond the follow-up available for many sleeve cohorts.

Among patients with diabetes, pooled 5-year mortality was 2.29% after RYGB versus 11.0% in controls. Cancer deaths were also less frequent after RYGB (OR 0.46; 95% CI, 0.31–0.70), although behavioral causes accounted for a larger share of deaths. Predominantly observational cohorts with differing case mixes make pooled, procedure-specific rates unsuitable for ranking operations.

KEY FINDING

4.34% versus 7.11% pooled mortality at 12 years favored RYGB over nonsurgical care. The diabetes subgroup also showed a substantial survival association.

Tuna Bilecik | Obesity Surgery, Oct. 12, 2026 | 10.1007/s11695-026-08981-y
Suggested by John D. Scott, MD

A prospective single-center cohort followed 35 women with severe obesity and insulin-treated diabetes after sleeve gastrectomy with transit bipartition. At 5 years, 23/35 (65.7%; 95% CI, 49.2–79.2%) were medication-free. Among 30 women retaining the original anatomy with complete data, mean HbA1c fell from 9.2% to 5.5%, and total weight loss averaged 35.7%.

Biochemical abnormalities affected 27/30 anatomy-retained completers at year 5, including hypoalbuminemia in 20.0% and vitamin D deficiency in 73.3%. One woman underwent reversal of the gastroileal pathway for refractory diarrhea. The uncontrolled, selected cohort cannot separate the procedure's effect from patient selection, despite the durable glycemic response observed.

KEY FINDING

65.7% of all enrolled women met the remission definition at 5 years. Nutritional abnormalities remained frequent despite preserved duodenal passage.

B — Science of Obesity Metabolism

Eleanor L. Watts, Amparo Gonzalez-Feliciano, Marc J. Gunter et al. | Nature Metabolism, Jun. 15, 2026 | 10.1038/s42255-026-01542-8
Suggested by Phil Schauer

A systematic review of 226 prospective-study articles included 1,520,512 incident cancers across 25 cancer types. Higher BMI was positively associated with 19 types, with substantial differences in effect size. For every 5 kg/m² increase in BMI, endometrial cancer risk was 58% higher (RR 1.58; 95% CI, 1.51–1.67), compared with a 3% increase for glioma (RR 1.03; 95% CI, 1.01–1.05).

Leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma added associations not reported in earlier major consensus reports. The bladder association came from never-smokers, while colorectal associations were stronger in men and ovarian associations stronger in East Asia. These exposure associations do not quantify how much a particular weight-loss treatment would reverse cancer risk.

KEY FINDING

19 cancer types showed positive associations with BMI. The large difference between endometrial cancer and glioma argues against treating obesity-related cancer risk as one uniform effect.

Jimmy Chun Yu Louie | Current Obesity Reports, Sep. 18, 2026 | 10.1007/s13679-026-00765-w
Suggested by John D. Scott, MD

Jimmy Chun Yu Louie's narrative review examines what daily totals lose when researchers measure ultra-processed-food intake. The usual exposure is the daily share of energy or food weight assigned to Nova group 4. He proposes retaining meal timestamps and eating context, because circadian and postprandial experiments show different metabolic responses to otherwise similar intake.

The proposal distinguishes changing food quantity from moving the same intake to another eating occasion, two different causal comparisons. Meal sequence and accompanying foods may also explain why identical daily totals yield different responses. The timing experiments did not specifically manipulate ultra-processed foods, so their extension to Nova group 4 remains a hypothesis.

KEY FINDING

Time-resolved exposure is the review's proposed alternative to relying on daily totals alone. It separates how much ultra-processed food is eaten from when and with what it is consumed.

John Deanfield, Jamie Lai Chun Wong, Michail Katsoulis et al. | Nature Medicine, Oct. 16, 2026 | 10.1038/s41591-026-04687-x
Suggested by Phil Schauer

A UK digital-care cohort enrolled 8,127 women, with 99.8% receiving tirzepatide and a mean dose of 9.5 mg weekly by month 6. Complete-case paired analyses found mean weight loss of 16.1 kg (95% CI, 15.9–16.2), or 15.5% of baseline weight. The program combined biochemical screening with video-supported follow-up and clinician-led titration rather than automatic dose escalation.

Retention at 6 months was 91.4%, and investigators reported no serious treatment-related adverse events. SheMed and eMed employees coauthored the study; both companies operated the program, which linked prescription refills to structured review. The uncontrolled self-pay cohort cannot determine how much the delivery model added to the medication's effect or how it compares with in-person care.

KEY FINDING

15.5% mean weight loss accompanied 91.4% retention at 6 months. The results describe a monitored digital treatment pathway rather than a comparison of digital and in-person services.

C — Metabolic Innovation and Technology

Yung Lee, Jerry Dang, Benjamin Clapp et al. | Surgery for Obesity and Related Diseases, Sep. 29, 2026 | 10.1016/j.soard.2026.08.032
Suggested by Samer Mattar

Editor's note: Board-selected revisit of an article covered in Issue 14. Disclosure: Editorial Board member Jerry Dang is a coauthor.

The ASMBS Emerging Technology and Procedures Committee reviews AI across preoperative assessment, operating rooms, follow-up, and administration. Its eight recommendations address implementation rather than a new efficacy trial. Examples include SOPHIA's 5-year weight prediction and computer vision for recognizing operative steps, separating prediction tasks from autonomous surgical action.

The committee frames AI as decision support and asks for prospective evaluation linked to registries, with performance assessment across BMI and demographic groups. It also distinguishes integrating a prediction into clinical workflow from merely developing an accurate model. Predominantly retrospective, single-center evidence limits claims that these applications improve patient outcomes.

KEY FINDING

Eight recommendations connect AI development with clinical oversight and evaluation. The committee emphasizes accountable decision support across the bariatric care pathway.

Mehrdad Biglari, Mathias Sioen, Maxime Bossuyt | Journal of Robotic Surgery, Oct. 8, 2026 | 10.1007/s11701-026-04042-9

A single surgeon's first 150 Hugo RYGB attempts yielded 147 robotic cases after three early laparoscopic conversions. Console-time analysis included 139 recordings and estimated a breakpoint at case 17.4 (95% CI, 14.3–20.5). Time fell by 9.2 minutes per case before that point versus 0.5 minutes afterward, with mean console time of 104.6 minutes across the recorded series.

Eleven of 147 patients had a documented complication (7.5%), and mean hospital stay was 2.03 days, with no deaths. The surgeon already had laparoscopic bariatric experience, and the nursing team had used Hugo in urology before this series. A console-time breakpoint in this setting does not establish a transferable proficiency threshold or comparative safety against laparoscopy.

KEY FINDING

Case 17.4 marked a change in the rate of console-time improvement. The finding describes an experienced surgeon's transition to robotic RYGB within an already trained robotic team.

Fractyl Health | Fractyl Health Investor Relations, Oct. 16, 2026 | Source ↗

Fractyl Health reported six-month results from REMAIN-1, a 308-participant randomized, sham-controlled study after tirzepatide discontinuation. Its modified intention-to-treat analysis found least-squares mean regain of 5.1% with Revita versus 8.2% with sham (p=0.0023). The sponsor-reported result concerns endoscopic duodenal resurfacing as a maintenance intervention after drug withdrawal.

Fractyl reported no device- or procedure-related serious adverse events, and 94% of related events occurred within 7 days. A post hoc subgroup receiving at least 20 cm of ablation regained 3.8% versus 8.2% with sham, compared with 4.7% after 12–18 cm. The pending 12-month co-primary endpoint leaves durability unresolved despite the six-month separation between randomized groups.

CONTEXT

Revita showed a 5.1% versus 8.2% regain in the primary six-month analysis. The smaller regain after longer ablation comes from exploratory subgroup comparisons.

D — Metabolic Marketplace

European Medicines Agency / CHMP | European Medicines Agency, Oct. 15, 2026 | Source ↗
Suggested by John D. Scott, MD

The European Medicines Agency's CHMP adopted a positive opinion for Eli Lilly's Foundayo, orforglipron, on October 15. The recommendation covers adult weight management and inadequately controlled type 2 diabetes. EMA lists six tablet strengths, 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg, placing an oral GLP-1 receptor agonist on the European marketing-authorization pathway.

EMA identifies gastrointestinal effects, including nausea, vomiting and diarrhea, as the most common adverse effects. It describes benefits for glycemic control and body weight alongside diet and physical activity, with detailed prescribing recommendations to follow authorization. The CHMP opinion is a regulatory recommendation, not a European Commission authorization or reimbursement decision.

CONTEXT

The CHMP issued a positive opinion for two adult indications. The next regulatory step is the European Commission's marketing-authorization decision.

Stryker and CMR Surgical | Stryker Newsroom, Oct. 12, 2026 | Source ↗

Stryker announced an approximately $400 million (£300 million) preferred-equity investment in CMR Surgical and exclusive U.S. sales rights for Versius. The agreement also gives Stryker an exclusive option to acquire 100% of CMR's outstanding equity in the future. CMR retains responsibility for portfolio development and commercialization outside the United States.

The arrangement pairs CMR's soft-tissue robotic platform with Stryker's existing endoscopy, visualization, and hospital sales relationships. It changes Versius's prospective commercial channel in the U.S., while leaving development with CMR. Regulatory approvals and closing conditions still apply, so the announcement describes a proposed alliance rather than a completed acquisition.

CONTEXT

The proposed alliance is anchored by approximately $400 million and exclusive U.S. sales rights. The acquisition option is a separate future possibility, not the transaction being completed now.

Viking Therapeutics | Viking Therapeutics Newsroom, Oct. 14, 2026 | Source ↗

Viking Therapeutics announced the SUNRISE phase 3 program for daily oral VK2735, a dual GLP-1/GIP agonist. SUNRISE-1 and SUNRISE-2 each target 560 adults, separating participants without diabetes from those with type 2 diabetes. Both randomized, double-blind trials compare 27.5, 35, and 55 mg daily with placebo over 68 weeks, with percentage weight change as the primary endpoint.

The oral program runs alongside VANQUISH, which evaluates weekly injectable VK2735 over 78 weeks in approximately 4,500 and 1,000 participants. Separate oral and injectable trials address different dosing routes, while the diabetes cohorts test response in a distinct metabolic population. This announcement reports trial initiation, so it adds no phase 3 efficacy or tolerability results.

CONTEXT

Two 68-week trials will test three oral VK2735 doses against placebo. The program separates adults with and without diabetes rather than pooling their weight responses.

Zealand Pharma | Zealand Pharma / GlobeNewswire, Oct. 13, 2026 | Source ↗
Suggested by John D. Scott, MD

Zealand Pharma announced a collaboration with Generate Biomedicines to develop multispecific proteins for obesity and other metabolic diseases. For two initial programs, Generate receives $30 million upfront and may earn up to $35 million in early preclinical milestones. Total potential milestones approach $1.2 billion, with tiered royalties tied to eventual worldwide sales.

Generate will lead research through candidate selection, combining computational protein design with experimental testing. Zealand then takes responsibility for clinical development, regulatory submissions, and commercialization, extending its discovery work beyond its existing peptide and small-molecule capabilities. The discovery-stage agreement provides no evidence of human efficacy or safety.

CONTEXT

$30 million upfront funds access to two initial protein programs. The much larger milestone total depends on subsequent development, regulatory, and commercial achievements.

Closing the gaps in knowledge...

Production Editor John D. Scott MD FACS | [email protected]

This issue's ballot: 6 of 6 board seats voted.
MBS Digest | October 20, 2026 | Vol. 2, Issue 15
For educational purposes only.